Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Patterson

Showing results (21-30 of 105) with videos related to

Pageof 11
Sort By:
Best Practice & Research. Clinical Haematology|November 10, 2016
Epigenomics in Waldenstrom's macroglobulinaemiaAntonio Sacco, Adriano Fenotti, Stefano Bazzana, et al.
Pilot and Feasibility Studies|September 28, 2018
Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF)Eric Kai Chung Wong, Justin Yusen Lee, Darryl P Leong, et al.
Age and Ageing|July 28, 2018
Nursing perspectives on the confusion assessment method: a qualitative focus group studyEric Kai-Chung Wong, Justin Yusen Lee, Anasuiya Sherhee Surendran, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kinChristina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Blood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.
British Journal of Haematology|April 14, 2016
Targeting Myddosome Assembly in Waldenstrom MacroglobulinaemiaXia Liu, Zachary R Hunter, Lian Xu, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Pageof 11

Showing results (21-30 of 105) with videos related to

Sort By:
Pageof 11
Best Practice & Research. Clinical Haematology|November 10, 2016
Epigenomics in Waldenstrom's macroglobulinaemiaAntonio Sacco, Adriano Fenotti, Stefano Bazzana, et al.
Pilot and Feasibility Studies|September 28, 2018
Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF)Eric Kai Chung Wong, Justin Yusen Lee, Darryl P Leong, et al.
Age and Ageing|July 28, 2018
Nursing perspectives on the confusion assessment method: a qualitative focus group studyEric Kai-Chung Wong, Justin Yusen Lee, Anasuiya Sherhee Surendran, et al.
Clinical Lymphoma, Myeloma & Leukemia|April 2, 2011
Associated malignancies in patients with Waldenström's macroglobulinemia and their kinChristina Hanzis, Rohit P Ojha, Zachary Hunter, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 23, 2011
Matrix metalloproteinase-8 is overexpressed in Waldenström's macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27Yangsheng Zhou, Xia Liu, Lian Xu, et al.
Blood|December 25, 2013
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesisZachary R Hunter, Lian Xu, Guang Yang, et al.
British Journal of Haematology|April 14, 2016
Targeting Myddosome Assembly in Waldenstrom MacroglobulinaemiaXia Liu, Zachary R Hunter, Lian Xu, et al.
Clinical Lymphoma & Myeloma|April 14, 2009
Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemiaBryan T Ciccarelli, Guang Yang, Evdoxia Hatjiharissi, et al.
British Journal of Haematology|May 14, 2011
Attainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaSteven P Treon, Guang Yang, Christine Hanzis, et al.
Blood|July 10, 2013
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemiaGuang Yang, Yangsheng Zhou, Xia Liu, et al.
Pageof 11